These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 11758580)

  • 1. The biotechnology industry organization's view on Hatch-Waxman reform.
    Schmickel D
    Food Drug Law J; 1999; 54(2):241-2. PubMed ID: 11758580
    [No Abstract]   [Full Text] [Related]  

  • 2. Protecting the balance of Hatch-Waxman: understanding the industry's new dynamics for the 21st century.
    Schroeder RG; Papas P
    Food Drug Law J; 2001; 56(1):19-26. PubMed ID: 11942348
    [No Abstract]   [Full Text] [Related]  

  • 3. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract]   [Full Text] [Related]  

  • 4. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 5. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ
    Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
    [No Abstract]   [Full Text] [Related]  

  • 6. Hatch-waxman changes debated.
    Chahine K
    Nat Biotechnol; 2000 Jul; 18(7):710-1. PubMed ID: 10888831
    [No Abstract]   [Full Text] [Related]  

  • 7. "Ganske" threatens biotechnology patents worldwide.
    Glaser V
    Nat Biotechnol; 1997 Feb; 15(2):121. PubMed ID: 9035128
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 9. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 11. Leading biotechnology companies quit the IBA.
    Gershon D
    Nature; 1990 Apr; 344(6266):481. PubMed ID: 2320118
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract]   [Full Text] [Related]  

  • 13. The Hatch-Waxman Act during patent prosecution and beyond.
    Mahn TG
    Food Drug Law J; 1999; 54(2):233-6. PubMed ID: 11758578
    [No Abstract]   [Full Text] [Related]  

  • 14. US courts narrow patent exemptions.
    Fox JL
    Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
    [No Abstract]   [Full Text] [Related]  

  • 15. Patenting drug products: anticipating Hatch-Waxman issues during the claims drafting process.
    Mahn TG
    Food Drug Law J; 1999; 54(2):245-53. PubMed ID: 11758582
    [No Abstract]   [Full Text] [Related]  

  • 16. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 17. Patent drop reveals pressures on industry.
    Lawrence S
    Nat Biotechnol; 2004 Aug; 22(8):930-1. PubMed ID: 15286630
    [No Abstract]   [Full Text] [Related]  

  • 18. How Cuozzo will impact the interplay between post grant proceedings and Hatch-Waxman litigation.
    Mishra N; Doody PA; Davé RS
    Pharm Pat Anal; 2017 Jan; 6(1):9-15. PubMed ID: 28181455
    [No Abstract]   [Full Text] [Related]  

  • 19. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How would patent reform legislation in the United States impact the pharmaceutical industry?
    Williams AW
    Expert Opin Ther Pat; 2015 Feb; 25(2):131-3. PubMed ID: 25387953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.